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SUMMARY
In a published case-control study (GSE152075) from SARS-CoV-2-positive (n =
403) and -negative patients (n = 50), we analyzed the response to infection
assessing gene expression of host cell receptors and antiviral proteins. The
expression analysis associated with reported risk factors for COVID-19 was
also assessed. SARS-CoV-2 cases had higher ACE2, but lower TMPRSS2,
BSG/CD147, and CTSB expression compared with negative cases. COVID-19 pa-
tients’ age negatively affected ACE2 expression. MX1 and MX2 were higher in
COVID-19 patients. A negative trend forMX1 andMX2was observed as patients’
age increased. Principal-component analysis determined that ACE2, MX1, MX2,
and BSG/CD147 expression was able to cluster non-COVID-19 and COVID-19 in-
dividuals. Multivariable regression showed that MX1 expression significantly
increased for each unit of viral load increment. Altogether, these findings support
differences in ACE2,MX1,MX2, and BSG/CD147 expression between COVID-19
and non-COVID-19 patients and point out toMX1 as a critical responder in SARS-
CoV-2 infection.
INTRODUCTION
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel virus that emerged in late 2019 in
Wuhan, China (World Health Organization, 2020). The World Health Organization (WHO) declared the
SARS-CoV-2 infection a pandemic health emergency as of January 31, 2020.
As of July 28, 2020, there are 16,812,755 confirmed cases of COVID-19 (coronavirus disease 2019), including
662,905 deaths reported to WHO from 216 countries and territories. The current worldwide COVID-19 fa-
tality rate (4%) is lower than that of SARS-CoV-1 (10%) and Middle East respiratory syndrome (MERS)-CoV
(32%) (World Health Organization, 2020). However, the total number of infected and dead people is much
higher than that due to the latter viruses.
Analyses for viral stability in aerosols and surfaces showed high similarity among SARS-CoV-2 and SARS-
CoV-1 (van Doremalen et al., 2020). This might imply that the differences in the epidemiologic viral fea-
tures probably arise from viral and host factors such as sex, comorbidities (Zheng et al., 2020), higher viral
loads, and/or the potential for asymptomatic individuals to spread the virus (Bai et al., 2020; Zou et al.,
2020).
SARS-CoV-2 invades host cells mainly via two receptors: angiotensin-converting enzyme 2 (ACE2) (Letko
et al., 2020; Yan et al., 2020) and Basigin or EMMPRIN (BSG/CD147) (Wang et al., 2020). This
mechanism results from the interaction between the host receptors and the viral spike glycoproteins
(S), after priming of this viral protein by the serine protease TMPRSS2 (Hoffmann et al., 2020). TMPRSS2
inhibition has been shown to block SARS-CoV-2 cell entry (Hoffmann et al., 2020). In addition to ACE2,
Wang et al. (2020) demonstrated that SARS-CoV-2 S protein also binds to BSG/CD147 (Ulrich and Pillat,
2020).
Sequential protease cleavage models have been proposed for activation of S protein of SARS-CoV and
MERS-CoV (Belouzard et al., 2009; Millet and Whittaker, 2014). Depending on the virus strain and the
1Universidad de Buenos






2CONICET - Universidad de
Buenos Aires, Instituto de
Quı́mica Biológica de la















iScience 23, 101585, October 23, 2020 ª 2020 The Author(s).




cell types infected, S protein may be cleaved by one or several host proteases, including cathepsins,
TMPRSS2, and BSG/CD147 (Park et al., 2016; Ulrich and Pillat, 2020). Thus, coronavirus cell entry, either
through plasma membrane or endocytosis, appears to be largely determined by the availability of these
proteases (Ou et al., 2020).
Of note, ADAMmetallopeptidase domain 17 (ADAM17) may exert a protective effect on SARS-CoV-2 infec-
tion. ADAM17 can release the ectodomains of a plethora of membrane-anchored factors, such as ACE2
(Lambert et al., 2005; Palau et al., 2020).
However, the lead roles of these factors in promoting viral infection in humans still remain elusive.
Although much attention has been placed in virus host cell receptors, little has been commented on anti-
viral effector proteins. It is well accepted that type I interferon (IFN) is essential in fighting viral infection by
induction of IFN-stimulated genes (ISGs), which work in synergy to inhibit viral replication via multiple
mechanisms (Li et al., 2018; Teijaro, 2016). The human myxovirus resistance genes (MX) encode GTPases
that are part of the antiviral response induced by type I/III IFNs (Verhelst et al., 2012). Humans encode
two different MX proteins, MX1 and MX2, which differ considerably in viral specificities and mechanisms
of action. MX1 has been shown to have wide antiviral activity against RNA and DNA viruses (Haller et al.,
2015), whereas MX2 action is limited to certain viruses such as HIV (Bhargava et al., 2018). Specifically,
MX1 has a direct effect on the viral ribonucleoprotein complex and its GTPase activity is essential for its
antiviral function. Greater MX1 expression correlated with better response to influenza A H1N1 pandemic
in 2009 (Verhelst et al., 2012).
The main therapeutic avenues to halt respiratory virus infection are targeting the virus directly or targeting
the host system. Although the first strategy is highly efficient, it is limited by the sensitivity/resistance of the
virus strain (McKimm-Breschkin, 2005; Monto, 2003). On the other hand, the second strategy is impaired by
having shown relatively low efficacy (Darwish et al., 2011; Ramos and Fernandez-Sesma, 2015). As the clin-
ical picture has evidenced that the ‘‘cytokine storm’’ triggered by these viruses causes severe lung injury
and lethality (Jose and Manuel, 2020), and that antiviral drugs are not effective in preventing such lung
injury, it is imperative to spawn new drugs that have the capacity to boost the host immune response while
controlling tissue damage as a consequence of these infections (Zheng et al., 2008).
There are no conclusive data evidencing the shifts in expression of host cell receptors and viral effectors
produced by SARS-CoV-2 infection in humans. Thus, in this work we analyzed gene expression profiles
in response to coronavirus infection in COVID-19 versus non-COVID-19 patients. We evaluated the expres-
sion of the main host cell receptors described for SARS-CoV-2 and potential antiviral genes. Our results
evidence high discrepancies regarding the expression of the reported main viral host cell receptors asso-
ciated with COVID-19, and point out to the relevance of MX1 to fight this disease.
RESULTS
Expression of Host Cell Receptors in SARS-CoV-2-Positive and -Negative Patients
We used the publicly available RNA sequencing (RNA-seq) dataset GSE152075 to evaluate the expression
of known host SARS-CoV-2 receptor genes: ACE2, TMPRSS2, BSG/CD147, CTSB, CTSL, and ADAM17
(Heurich et al., 2014; Hoffmann et al., 2020; Simmons et al., 2005; Ulrich and Pillat, 2020; Zhou et al.,
2015). This set consists of transcriptome data from nasopharyngeal swabs from 430 SARS-CoV-2-positive
and 54 SARS-CoV-2-negative patients. We excluded 27 SARS-CoV-2-positive and 4 SARS-CoV-2-negative
samples from the downstream analyses because the RNA-seq data from these individuals was of low quality
(>70% of genes resulting in 0 sequencing reads). Patient demographics are available in Table S1.
Results evidenced that COVID-19 patients had higher ACE2 expression compared with non-COVID-19 pa-
tients (Figure 1A.I; p = 1.7 3 107). On the contrary, TMPRSS2 (Figure 1B.I), BSG/CD147 (Figure 1C.I), and
CTSB (Figure 1D.I) expression was lower in the COVID-19 group (p = 3.4 3 109, p = 2.0 3 1012, and p =
6.8 3 109, respectively). Non-statistical differences for CTSL and ADAM17 expression were observed be-
tween SARS-CoV-2-positive and -negative patients (Figures 1E.I and 1F.I, respectively).
As the reported risk factors for SARS-CoV-2 infection include age and sex, we next assessed the association
between these risk factors and the host receptors’ gene expression. We did not find gene expression
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differences between sex (Figures 1A.II–1F.II). When analyzing the association between gene expression
and age, we found that the older the COVID-19 patient, the lower the expression for ACE2 (Figure 1A.III;
P-trenddecreasing = 0.002) and CTSB (Figure 1D.III; P-trenddecreasing = 0.008). We did not observe an associ-
ation between age and gene expression for the other receptors in the COVID-19 group (Figures 1B.III,
1C.III, 1E.III, and 1F.III). For SARS-CoV-2-negative donors, no variation in gene expression associated
with age was observed (Figures 1A.III–1F.III).
Expression of Antiviral-Associated Genes in SARS-CoV-2-Positive and -Negative Patients
Next, we assessed antiviral-associated genes that play a crucial role in halting viral replication via multi-
ple mechanisms: MX1, MX2, NRF2, IRF3, HIF1A, and HMOX1 (Chiang and Liu, 2018; Espinoza et al., 2017;
Haller et al., 2015; Hassan et al., 2020; Hong et al., 2009) (Figure 2). MX1 (Figure 2A.I) and MX2 (Fig-
ure 2B.I) expression was significantly higher in COVID-19 patients (p = 7.2 3 1011 and p = 2.3 3
1013, respectively) compared with the non-COVID-19 group. No significant differences were observed
between patients of different sex for any of the genes assessed (Figures 2A.II–2F.II). Interestingly, we
observed a negative trend for MX1 (Figure 2A.III; P-trenddecreasing = 0.004) and MX2 (Figure 2B.III;
P-trenddecreasing = 0.012) expression as patients’ age increased. In addition, NRF2 and IRF3 expression
was significantly lower in COVID-19 patients (Figures 2C.I and 2D.I; p = 0.010 and p = 5.0 3 104, respec-
tively), and NRF2 also showed a significant P-trend in COVID-19 patients grouped by age (Figure 2C.III;
P-trenddecreasing = 0.004). No statistical differences were observed when comparing HMOX1 and HIF1A
expressions (Figures 2E and 2F). For SARS-CoV-2-negative donors no variation in gene expression asso-
ciated with age was observed (Figures 2A.III–2F.III).
Gene Correlation and Principal-Component Analysis
Next, we performed pairwise Spearman correlation analyses (Figure 3A and Table S2) for host receptors
and antiviral gene expression levels of the host receptors and antiviral genes. We considered all patients
(Corr.), only non-COVID-19 patients (Neg.), and only COVID-19 patients (Pos.). Black boxes highlight
statistically significant correlation among genes for COVID-19 patients, whereas correlations for the
same pairs in non-COVID-19 patients appeared non-significant (Figure 3A). Of note, ACE2 showed an
r = 0.416 (p < 1 3 1015) with MX1, whereas MX2 showed an r = 0.423 (p < 1 3 1015) with
HMOX1, an r = 0.595 (p < 1 3 1015) with CTSB, and an r = 0.450 (p < 1 3 1015) with CTSL (Figure 3A
and Table S2).
Interestingly, althoughMX1 andMX2 respond to SARS-CoV-2 infection (Figures 2A and 2B), the correlation
analysis highlightsMX2 positive correlation for both non-COVID-19 and COVID-19 patients (Figure 3A and
Table S2; r = 0.642, p = 4.97 3 107 and r = 0.899, p < 1 3 1015, respectively), whereas MX1 only displays
positive correlation for COVID-19 patients. These data suggest that MX1 might be more specific in the
response to SARS-CoV-2 than MX2.
In parallel, we performed a principal-component analysis (PCA), which is a dimensionality reduction tech-
nique, used to increase the interpretability of the dataset, minimizing at the same time information loss and
maximizing variance. In this dataset, the principal component (PC) 1 explained 43.8% of the variance
among samples (Figure 3B). Only the infection status is shown because none of the other assessed vari-
ables (age, sex, and RNA-seq batch) clustered the samples on PC1. The PC2 is responsible for 13.1% of
the variability, and the expression of ACE2,MX1,MX2, and BSG/CD147 seemed to drive the difference be-
tween non-COVID-19 and COVID-19 individuals (Figure 3B). Furthermore, we plotted the combined
expression of ACE2, BSG/CD147, and MX1 (Figure 3C.I) and ACE2, BSG/CD147, and MX2 (Figure 3C.II).
These combinations were selected because MX1 and MX2 gene expression were highly correlated for
both non-COVID-19 and COVID-19 patients (Figure 3A and Table S2). The graphs show distinct 95% con-
fidence ellipsoids, generated by 3-gene expression patterns, able to cluster non-COVID-19 and COVID-19
individuals (Figure 3C).
Figure 1. Expression of Host Cell Receptor Genes in COVID-19 and Non-COVID-19 Patients
(A–F) Gene expression analysis for host cell receptor genes (A) ACE2, (B) TMPRSS2, (C) BSG/CD147, (D) CTSB, (E) CTSL, and (F) ADAM17.
(I) COVID-19 versus non-COVID-19 patients (p values correspond to Wilcoxon rank-sum test); (II) COVID-19 and non-COVID-19 patients by sex (p values
correspond to Wilcoxon rank-sum test); (III) COVID-19 and non-COVID-19 patients categorized by age groups (p values correspond to decreasing
Jonckheere-Terpstra trend test). Statistical significance was set at p < 0.05. NS: not significant.
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SARS-CoV-2 Viral Load Association with Gene Expression
To assess the correlation between gene expression and SARS-CoV-2 viral load, we used the PCR cycle
threshold (Ct) of the N1 viral gene amplification as a surrogate variable for viral load. We found a positive
correlation between expression of ACE2 (Figure 4A.I; r = 0.260, p = 2.63 107),CTSL (Figure 4A.I; r = 0.110,
p = 0.034),MX1 (Figure 4A.II; r = 0.230, p = 7.13 106), andMX2 (Figure 4A.II; r = 0.190, p = 2.03 104), with
SARS-CoV-2 viral load. Of note,MX1 correlation with viral load appears to be stronger than the correlation
observed for MX2, further supporting MX1 enhanced response to SARS-CoV-2, compared with MX2.
On the other hand, we observed a negative correlation between BSG/CD147 expression (Figure 4A.I;
r = 0.120, p = 0.015) and viral load. These results were further supported by PCA that showed a rough
clustering of COVID-19 samples according to patients’ viral load (high, medium, low) mainly by ACE2,
BSG/CD147, MX1, and MX2 (Figure 4B).
Next, we analyzed the pairwise correlations for BSG/CD147, ACE2, MX1, and MX2 considering viral
load in COVID-19 patients. As expected, results showed positive and significant correlations for all
genes in all comparisons (Figure 5A). Although a high correlation was observed for MX1 versus
MX2 + viral load (Figure 5A; r = 0.907, p = 2.2 3 1016), this is probably due to the collinearity between
MX1 and MX2.
Finally, we assessed the association between each gene with viral load using a linear multivariable regres-
sion analysis adjusted by age. Results indicate that viral load can explain variations in MX1, BSG/CD147,
and ACE2 expression (Figure 5B.I; p = 0.004, p = 0.038, and p = 0.084, respectively). However, MX2
does not appear to behave dependently from viral load when considering patient’s age (Figure 5B.I; p =
0.590). When further adjusting the model to consider the viral load-dependent genes, we found that for
each unit of increase in viral load, MX1 expression increased 26.76 units, ACE2 expression increased
1.03 units, and BSG/CD147 expression decreased 1.35 units (Figure 5B.II; p < 0.001, p = 0.170 and p <
0.001, respectively). Altogether these results point out to MX1 as the critical responder in SARS-CoV-2
infection.
DISCUSSION
Respiratory epithelium is the primary barrier that defends the host against respiratory pathogens. When
respiratory viruses overcome the first barrier, attachment and internalization into epithelial cells is the
next step to start its replication.
ACE2mediates SARS-CoV-2 entry to the cells by binding to the S protein (Hoffmann et al., 2020). Its primary
physiological function is the conversion of angiotensin II to angiotensin-(1–7). There are controversial data
concerning therapies that could modulate ACE2 expression, like angiotensin receptor blockers (ARBs), as
they may cause an initial up-regulation with further down-regulation of ACE2 expression during SARS-
CoV-2 infection, still not ascertaining whether this may lead to harmful or beneficial effects (Vaduganathan
et al., 2020). Our analysis evidenced an increase of ACE2 expression in COVID-19 versus non-COVID-19
patients correlating with viral load.
TMPRSS2 is currently also in the main scene regarding key SARS-CoV-2 host cell receptors (Hoffmann et al.,
2020). TMPRSS2-mediated cleavage of S protein has been described to be necessary for SARS-CoV and
MERS-CoV productive infections (Glowacka et al., 2011; Matsuyama et al., 2010; Shulla et al., 2011).
Recently, this same process has been reported for SARS-CoV-2 (Hoffmann et al., 2020). However, our anal-
ysis reflects a down-regulation of TMPRSS2 in COVID-19 patients. Similarly, BSG/CD147, another key re-
ceptor that binds to the S protein (Wang et al., 2020), appears to be down-regulated in COVID-19 patients
with lower levels associated with higher viral load. These results may suggest that SARS-CoV-2 infection
may prompt a selective mechanism of host cell receptors, and thus, targeting TMPRSS2 and BSG/
CD147 might not necessarily be the most effective strategy to halt infection.
Figure 2. Expression of Host Antiviral Effector Genes in COVID-19 and Non-COVID-19 Patients
(A–F) Gene expression analysis for the selected host cell receptor genes (A) MX1, (B) MX2, (C) NRF2, (D) IRF3, (E) HIF1A, and (F) HMOX1.
(I) COVID-19 versus non-COVID-19 patients (p values correspond to Wilcoxon rank-sum test), (II) COVID-19 and non-COVID-19 patients by sex (p values
correspond to Wilcoxon rank-sum test), and (III) COVID-19 and non-COVID-19 patients categorized by age groups (p values correspond to decreasing
Jonckheere-Terpstra trend test). Statistical significance was set at p < 0.05. NS: not significant.
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Despite host cell receptors being critical targets to prevent viral infection, it is also important to consider
the second line of defense in response to the pathogen. One of the antiviral effectors is MX1 (Haller
et al., 2015). MX genes exist in nearly all vertebrate genomes, and they are active mainly against RNA
viruses. MX1 is an effector protein of the IFN system (Verhelst et al., 2012; Zav’yalov et al., 2019). Studies
report that MX1 generates a protective antiviral response controlling the expression of key modulator
molecules associated with influenza A virus lethality; effects increased under IFN-ɑ stimulation (Cilloniz
et al., 2012; Haller et al., 2015). MX2 is also a key contributor to the type I IFN-induced post-entry
inhibition of HIV-1 infection (Dicks et al., 2018). Currently, there are several ongoing clinical trials for
COVID-19 prevention and/or treatment using type I or III IFNs (NCT04343976 [Phase II], NCT04385095
[Phase II], NCT04354259 [Phase II], NCT04293887 [Early Phase I], NCT04344600 [Phase II],
NCT04320238 [Phase III], NCT04388709 [Phase II]). However, IFN administration could enhance a ‘‘cyto-
kine-storm’’ causing a hyper-inflammatory response and contributing to multiple organ failure. Of note,
recent reports showed that COVID-19 patients present a defective type I IFN response characterized by
decreased production and activity, with consequent deregulation of ISGs. The authors suggest type I IFN
deficiency in the blood as a hallmark of severe COVID-19 and also discuss the risk of using drugs that
interfere with the IFN pathway (Hadjadj et al., 2020).
As shown in this work,MX1 andMX2 expression levels are higher in COVID-19 patients. Interestingly, both
MX1 and MX2 expression increases significantly with viral load and on the contrary, their expression is
reduced with age. Epidemiologic reports by the Centers for Disease Control and Prevention (CDC) have
shown increased severity in older patients (Centers for Disease Control and Prevention, 2020). Although
an important limitation of this study is the lack of clinical data accounting for disease severity, there is
no correlation between age and viral load in the COVID-19 patients assessed (r = 0.031, p = 0.58). Thus,
we might speculate that the loss of MX1 and MX2 with age may be associated with higher risk for severe
illness.
Other ways of increasing and sustainingMX1 expression to fight SARS-CoV-2 infection may be the use of a
previously US Food and Drug Administration-approved drug known as hemin, a well-known inducer of
HMOX1, and a modulator of MX1 expression independent from IFN activation. Although our results
show no significant alteration in HMOX1 expression, there is sound literature referring to its interference
with viral infections (Espinoza et al., 2017). Some examples include the use of CoPP, which induces
HMOX1, promoting IRF3 phosphorylation and nuclear translocation, and subsequently expression of
MX1 (Ma et al., 2019). The protective role of HMOX1 against viral infection has also been demonstrated
for dengue, hepatitis C, hepatitis B, Ebola, Zika, and HIV-1 infections, revealing that HMOX1 signaling
pathway was a promising strategy for treating these infections (Devadas and Dhawan, 2006; Hill-Batorski
et al., 2013; Huang et al., 2017; Lee et al., 2014; Protzer et al., 2007; Tseng et al., 2016). Furthermore, androg-
rapholide, an anti-inflammatory and anti-oxidative compound that induces HMOX1, was suggested as a
potential inhibitor of the main protease of SARS-CoV-2 (Enmozhi et al., 2020).
To increase the interpretability of the data we performed pairwise Spearman correlation and PCA. Results
obtained were able to cluster non-COVID-19 and COVID-19 individuals based on ACE2, MX1, and BSG/
CD147 expression. Furthermore, when performing a multivariable regression analysis including viral
load, age, and selected genes, MX1 and BSG/CD147 appear to significantly correlate with viral load inde-
pendently from the other gene expressions included in the model and age. However, the increase in MX1
compared with BSG/CD147, per unit of viral infection, is strikingly higher (>15-fold).
In conclusion, these results highlightMX1 as a solid responder to SARS-CoV-2 pointing out to the relevance
of evaluating approved drugs able to boost MX1 expression and halt infection. Further experimental
research will be needed to ascertain the antiviral function of MX1 against SARS-CoV-2.
Figure 3. Gene Correlation and Principal-Component Analysis (PCA)
(A) Pairwise Spearman correlation matrix analysis between all genes of interest. The upper half displays the Spearman coefficients (r) considering all patients
(Corr), non-COVID-19 patients (Neg.), or COVID-19 patients (Pos.). Black boxes highlight genes that have significant correlation only in COVID-19 patients.
Statistical significance *p < 0.05; **p < 0.01; ***p < 0.001. The lower half displays the scatterplots.
(B) PCA biplot of gene expression data showing a rough segregation of non-COVID-19 and COVID-19 samples. Each point represents one individual, and
the arrows depict the gene expression profile; black arrows show the 4 genes that have the greatest weight in driving the difference between the groups.
(C) 3D scatter plots for (I) ACE2, MX1, and BSG/CD147 and (II) ACE2, MX2, and BSG/CD147.
ll
OPEN ACCESS
8 iScience 23, 101585, October 23, 2020
iScience
Article
Limitations of the Study
Our analysis in this article has limitations worth mentioning. Although we performed an extensive anal-
ysis with a public RNA-seq dataset containing 484 human samples, we were not able to access com-
plete clinical records because they are not publicly available (e.g., illness severity). In addition, RNA-
seq raw data were unavailable; therefore, we were not able to perform the pre-processing and
Figure 4. Correlation Analysis between Gene Expression and SARS-CoV-2 Viral Load in COVID-19 Patients
(A) Viral load and gene expression correlation for (I) ACE2, TMPRSS2, BSG/CD147, CTSB, CTSL, and ADAM17 and for (II)MX1,MX2,NRF2, IRF3, HIF1A, and
HMOX1. Viral load was defined by the cycle threshold (Ct) of the N1 viral gene amplification during diagnostic PCR. Spearman coefficient (r) is shown for each
correlation. Statistical significance was set at p < 0.05. NS: not significant.
(B) Principal-component analysis biplot of gene expression data showing a rough segregation of non-COVID-19 and COVID-19 patients stratified by low
(Ct > 24), medium (Ct = 24–19), and high (Ct < 19; blue) viral load. Each point represents one individual, and the arrows depict the gene expression profile;
black arrows show the 4 genes that have the greatest weight in driving the difference between the groups.
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alignment of sequences. However, we were able to curate samples excluding those that did not have
reads for >70% of genes. Finally, some individuals suffered from other bacterial or viral infections that
might confound the findings.
Resource Availability
Lead Contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by
the Lead Contact, Geraldine Gueron (ggueron@iquibicen.fcen.uba.ar).
Materials Availability
This study did not generate new unique reagents.
Data and Code Availability
This study did not generate new datasets.
Figure 5. Association between Viral Load and Gene Expression
(A) Dot plots representing pairwise correlations for BSG/CD147,ACE2,MX1, andMX2 considering viral load in COVID-19 patients. For each comparison, the
independent variable is plotted in the x axis and the dependent variable is plotted in the y axis. For all cases, viral load was considered as an independent
variable. Viral load is represented as a color scale.
(B) Forest plots representing multivariable regression analysis. Model (I) considering as covariates: individual gene expression, viral load, and age; and
model (II) considering as covariates: viral load, age, and all genes. Statistical significance was set at p < 0.05. NS: not significant.
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All methods can be found in the accompanying Transparent Methods supplemental file.
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TMPRSS2 and ADAM17 cleave ACE2
differentially and only proteolysis by TMPRSS2
augments entry driven by the severe acute
respiratory syndrome coronavirus spike protein.
J. Virol. 88, 1293–1307.
Hill-Batorski, L., Halfmann, P., Neumann, G., and
Kawaoka, Y. (2013). The cytoprotective enzyme
heme oxygenase-1 suppresses Ebola virus
replication. J. Virol. 87, 13795–13802.
Hoffmann, M., Kleine-Weber, H., Schroeder, S.,
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Table S1. Patient demographics for the GSE152075 dataset. Related to all figures. 
 non-COVID-19 COVID-19 P-value 
Number of patients 50 403  
Sex Male 22 (44%) 166 (41.2%)  
Female 28 (56%) 187 (46.4%) 0.763 a 
Unknown - 50 (12.4%)  
Age 
(years) 
Range 12 - 91 2 - 91  
Inter Quartile Range 29-63 41-71  
Median 46.5 56  
Media 46.5 55.6 0.002 b 
<30s 13 (26%) 41 (10.2%)  
30s 5 (10%) 51 (12.7%)  
40s 10 (20%) 55 (13.6%)  
50s 7 (14%) 80 (19.9%)  
60s 8 (16%) 50 (12.4%)  
≥70 7 (14%) 110 (27.3%) 0.012
 c 
Unknown - 16 (3.9%)  
Viral load High (Ct <19) - 106 (26.3%)  
Mid (Ct 19-24) - 197 (48.9%)  
Low (Ct >24) - 84 (20.9%)  
Unknown - 16 (3.9%)  
Table contains the number and % of COVID-19 and non-COVID-19 patients according to sex, age and viral load.a Fisher's exact; 





Table S2. Host receptor and antiviral gene correlation in all patients (Global), non-







r P-value r P-value r P-value 
ACE2 
ADAM17 -0.013 0.786 0.138 0.340 -0.008 0.878 
BSG 0.045 0.343 0.093 0.522 0.139 0.005 
CTSB 0.177 1.59x10-04 0.170 0.237 0.267 5.22x10-08 
CTSL 0.291 2.85x10-10 0.367 0.009 0.284 6.19x10-09 
HIF1A 0.233 5.61x10-07 0.146 0.312 0.233 2.28x10-06 
HMOX1 0.180 1.15x10-04 0.053 0.714 0.210 2.22x10-05 
IRF3 0.050 0.284 0.178 0.217 0.086 0.084 
MX1 0.439 <1x10-15 0.132 0.361 0.416 <1x10-15 
MX2 0.402 <1x10-15 0.168 0.244 0.359 1.07x10-13 
NRF2 0.291 2.82x10-10 0.090 0.534 0.360 8.22x10-14 
ADAM17 NRF2 0.189 5.17x10-05 0.207 0.150 0.187 1.57x10-04 
BSG 
ADAM17 0.182 9.70x10-05 0.106 0.464 0.195 8.27x10-05 
HIF1A 0.313 1.01x10-11 0.176 0.221 0.366 3.26x10-14 
HMOX1 0.510 <1x10-15 0.398 0.004 0.531 <1x10-15 
IRF3 0.390 <1x10-15 0.504 1.92x10-04 0.350 5.01x10-13 
MX1 0.270 5.52x10-09 0.461 0.001 0.412 <1x10-15 
MX2 0.200 1.76x10-05 0.072 0.617 0.379 3.55x10-15 
NRF2 0.483 <1x10-15 0.590 6.59x10-06 0.466 <1x10-15 
CTSB 
ADAM17 0.212 5.07x10-06 0.008 0.954 0.232 2.55x10-06 
BSG 0.674 <1x10-15 0.707 9.88x10-09 0.623 <1x10-15 
CTSL 0.474 <1x10-15 0.686 3.91x10-08 0.492 <1x10-15 
HIF1A 0.509 <1x10-15 0.281 0.048 0.572 <1x10-15 
HMOX1 0.579 <1x10-15 0.466 0.001 0.590 <1x10-15 
IRF3 0.475 <1x10-15 0.613 2.26x10-06 0.437 <1x10-15 
MX1 0.499 <1x10-15 0.465 0.001 0.657 <1x10-15 
MX2 0.400 <1x10-15 -0.012 0.933 0.595 <1x10-15 









r P-value r P-value r P-value 
CTSL 
ADAM17 0.169 2.91x10-04 0.303 0.033 0.162 0.001 
BSG 0.237 3.31x10-07 0.599 4.41x10-06 0.237 1.56x10-06 
HIF1A 0.526 <1x10-15 0.261 0.067 0.551 <1x10-15 
HMOX1 0.469 <1x10-15 0.412 0.003 0.477 <1x10-15 
IRF3 0.297 1.14x10-10 0.691 2.85x10-08 0.267 5.37x10-08 
MX1 0.452 <1x10-15 0.507 1.71x10-04 0.456 <1x10-15 
MX2 0.427 <1x10-15 0.262 0.066 0.450 <1x10-15 
NRF2 0.473 <1x10-15 0.555 2.94x10-05 0.480 <1x10-15 
HIF1A 
ADAM17 0.189 5.40x10-05 0.112 0.438 0.203 4.09x10-05 
NRF2 0.687 <1x10-15 0.544 4.39x10-05 0.713 <1x10-15 
HMOX1 
ADAM17 0.157 0.001 0.039 0.786 0.165 0.001 
HIF1A 0.578 <1x10-15 0.402 0.004 0.598 <1x10-15 
IRF3 0.301 5.88x10-11 0.358 0.011 0.288 4.03x10-09 
NRF2 0.550 <1x10-15 0.322 0.023 0.565 <1x10-15 
IRF3 
ADAM17 0.257 2.99x10-08 0.303 0.032 0.247 5.21x10-07 
HIF1A 0.249 7.95x10-08 0.175 0.223 0.271 3.11x10-08 
NRF2 0.388 <1x10-15 0.585 8.01x10-06 0.353 2.8x10-13 
MX1 
ADAM17 0.146 0.002 0.312 0.028 0.177 3.64x10-04 
HIF1A 0.593 <1x10-15 0.465 0.001 0.623 <1x10-15 
HMOX1 0.432 <1x10-15 0.429 0.002 0.470 <1x10-15 
IRF3 0.250 7.28x10-08 0.658 2.08x10-07 0.288 3.90x10-09 
MX2 0.897 <1x10-15 0.642 4.97x10-07 0.899 <1x10-15 
NRF2 0.652 <1x10-15 0.593 5.66x10-06 0.745 <1x10-15 
MX2 
ADAM17 0.189 4.94x10-05 0.363 0.01 0.226 4.48x10-06 
HIF1A 0.624 <1x10-15 0.417 0.003 0.666 <1x10-15 
HMOX1 0.362 1.78x10-15 0.079 0.587 0.423 <1x10-15 
IRF3 0.235 4.42x10-07 0.277 0.051 0.319 5.61x10-11 









r P-value r P-value r P-value 
TMPRSS2 
ACE2 0.138 0.003 0.182 0.206 0.220 8.66x10-06 
ADAM17 0.291 2.68x10-10 0.168 0.243 0.296 1.43x10-09 
BSG 0.432 <1x10-15 0.534 6.55x10-05 0.364 4.71x10-14 
CTSB 0.516 <1x10-15 0.475 4.87x10-04 0.473 <1x10-15 
CTSL 0.264 1.22x10-08 0.495 2.61x10-04 0.273 2.67x10-08 
HIF1A 0.291 2.64x10-10 0.221 0.123 0.324 2.51x10-11 
HMOX1 0.313 8.95x10-12 0.315 0.026 0.298 1.03x10-09 
IRF3 0.431 <1x10-15 0.565 1.95x10-05 0.390 4.44x10-16 
MX1 0.290 3.35x10-10 0.679 5.88x10-08 0.393 2.22x10-16 
MX2 0.266 9.16x10-09 0.380 0.006 0.404 <1x10-15 
NRF2 0.485 <1x10-15 0.549 3.63x10-05 0.473 <1x10-15 
Table contains the r value and P-value for gene correlations. Genes that have significant correlation in COVID-19 patients but 
non-significant correlation in non-COVID-19 are highlighted in bold. Data was taken from the GSE152075 dataset. 
 
TRANSPARENT METHODS 
Transcriptome datasets selection and study population 
We browsed the Gene Expression Omnibus (GEO) repository (Barrett et al., 2013) using the 
following keywords and expressions: [(COVID) OR (COVID-19) OR (CORONAVIRUS) OR 
(SARS-CoV-2) OR (2019-nCoV)] AND [(transcriptomics) OR (RNA-seq) OR (microarray) OR 
(expression) OR (transcriptome)]. All potentially relevant datasets were further evaluated in 
detail by 2-3 authors. The eligibility criteria included: (i) publicly available transcriptome data; 
(ii) detailed sample information; (iii) detailed protocol information; (iv) ≥ 60 samples.  
We selected the GSE152075 dataset, which contains RNA-seq data from 430 SARS-CoV-2 
positive and 54 negative patients (Lieberman et al., 2020). RNA was isolated from 
nasopharyngeal swabs and sequenced in an Illumina NextSeq 500 instrument. Reads were 
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pseudoaligned to the human transcriptome and pre-processed by the authors of the original 
study (Lieberman et al., 2020). Clinico-pathological information included age, sex, and viral 
load (expressed as cycle threshold (Ct) by RT-qPCR for the N1 viral gene at time of 
diagnosis). The interpretation for viral load was: the higher the viral load, the lower de Ct. 
RNA-seq analysis 
We downloaded the pseudoaligned and pre-processed RNA-seq data. We removed samples 
with >70% of total genes with 0 sequences reads considering them as very low-quality 
samples that might introduce a bias. Normalization, batch effect correction and differential 
expression were performed with R package DEseq2 v1.28.1 (Love et al., 2014). 
Statistical analyses 
Wilcoxon rank sum test was performed to determine statistical differences between 
categorical groups. Age was categorized according to the WHO guidelines (“World Health 
Organization 2020 - Novel Coronavirus (2019-nCoV) Situation Report - 1,” n.d.): <30 years 
old, every 10 years between 30-70 years old and ≥70 years old. Two-sided, increasing and 
decreasing Jonckheere-Terpstra trend tests (with 500 permutations) were used to determine 
statistical trends between gene expression and age groups. To study pairwise correlations 
between continuous variables, Spearman's rank correlation coefficient was calculated. 
Multilinear regression analyses were performed to determine the correlation between the 
expression of two genes and viral load. To estimate the regression coefficients of the 
different models, we used a multivariable regression including gene expression, viral load 
and age as covariates.  
All statistical analyses were done in Stata v14 (StataCorp LLC, College Station, TX, USA) or 
GraphPad Prism (La Jolla, CA, USA). Statistical significance was set as P<0.05. We did not 
correct P value for multiple testing. 
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Principal Component Analysis (PCA) was done with the factorextra and dplyr packages in R 
(Kassambara and Mundt, 2020). We included only the selected host receptors and antiviral 
genes.  
All results were plotted using ggplot2 (Wickham and Hadley, 2016), ggpubr (Kassambara, 
2020), GGally (Schloerke et al., 2020), canvasXpress (Neuhaus and Brett, 2020) in R, or 
GraphPad Prism (La Jolla, CA, USA). 
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